Enalapril

證據等級: L5

預測適應症: 0 個

Enalapril: Evaluation on Hold — Insufficient Evidence Pack Data

One-Sentence Summary

Enalapril is a well-established ACE (Angiotensin-Converting Enzyme) inhibitor widely used globally for hypertension, heart failure, and diabetic nephropathy. However, this Evidence Pack contains no TxGNN-predicted new indications, no original indication records, and critical data gaps across all evaluation domains. A complete drug repurposing evaluation cannot be performed until the missing data are resolved.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	None — `predicted_indications` array is empty
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction not yet generated; no supporting studies retrievable)
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing rationale can be constructed because the predicted_indications array is empty in this Evidence Pack — TxGNN has not generated any candidate indications for Enalapril in the current dataset run.

Furthermore, the mechanism of action is flagged as a high-severity data gap (DG002). Without MOA data, even a hypothesis-driven mechanistic bridge between an original indication and a potential new indication cannot be formulated.

The original approved indications field is also empty (original_indications: []), which may indicate that a regulatory data pull (e.g., from FDA Philippines or equivalent) was not completed before this pack was assembled.

Clinical Trial Evidence

No TxGNN-predicted indication is available in this Evidence Pack. Indication-specific clinical trial evidence cannot be retrieved or presented.

Literature Evidence

No TxGNN-predicted indication is available in this Evidence Pack. Indication-specific literature evidence cannot be retrieved or presented.

Philippines Market Information

Enalapril is currently not registered in the Philippines under this Evidence Pack. No product authorizations were found.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	No registered products found	—	—

Note: Given that Enalapril is a long-established, off-patent ACE inhibitor available in most global markets, an independent verification with FDA Philippines (Food and Drug Administration, Philippines) is recommended, as the absence of records may reflect a data ingestion issue rather than a true absence from the market.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields — key warnings, contraindications, and drug–drug interactions — are flagged as data gaps in this Evidence Pack. Specifically:

DG001 (Blocking): Package insert warnings and contraindications were not retrieved. This blocks entry into safety pre-screening (S1).

DDI query: Returned not_found (0 interactions recorded).

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is critically incomplete across all four evaluation pillars — regulatory data, TxGNN predictions, MOA, and safety — making it impossible to assess repurposing viability or generate a meaningful evidence-based recommendation at this time.

To proceed, the following is needed:

[Critical — Blocking] Re-run the TxGNN prediction pipeline to populate predicted_indications for Enalapril (DB00584); the current empty array suggests the prediction step was not completed
[Critical — Blocking] Resolve DG001: Download and parse the package insert PDF from the TFDA (or FDA Philippines equivalent) to extract key warnings and contraindications
[High] Resolve DG002: Query the DrugBank API for Enalapril’s mechanism of action to enable mechanistic plausibility analysis
[High] Confirm original approved indications from at least one regulatory source (e.g., FDA Philippines, TFDA, EMA, or FDA USA)
[Medium] Independently verify Philippines FDA registration status, as Enalapril is a widely available generic; a zero-registration result may indicate a data pipeline issue
[Medium] Re-query DDI databases (e.g., DrugBank interactions endpoint) once the drug identity is confirmed, as the not_found status is unexpected for a drug with known interaction profiles
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.